Nitric oxide production via nitric oxide synthase may be a downstream effector of kit and abrogated in response to kit inhibition, leading to collapse of the vascular architecture.21,22 Alternatively, imatinib may target kit and/or PDGFR signaling in tumor-associated endothelial cells or pericytes.23–25. This evidence concerns the gene KIT and neoplasm.